Tue, Oct 21, 2014, 5:11 AM EDT - U.S. Markets open in 4 hrs 19 mins

Recent

% | $
Quotes you view appear here for quick access.

Curis, Inc. Message Board

  • pits200 pits200 Apr 30, 2013 2:42 PM Flag

    Hard Come, Easy Go...

    Ridiculous, how many times has this stock done this in the past few months. This is a day trader stocks wet dream. Basing a biotechs numbers on earnings is ridiculous, everyone here who talks fundamentals should please stop, this stock has never held according to any of the fundamental charts.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree that the day traders have a lot to do with this but at the same time; the shorts will cover and help these kinds of short-lived increases. The fundamentals are actually with this price of 3 to 4 since CRIS royalties are at the lowest end of normal. They have to renegotiate the rate with Roche. When I was working on a royalty agreement with Sanofi, we were able to double the rate!
      The valuation of CRIS comes from the fact that investors are forgetting the AU market and soon-to-come approval. Their other programs are in Phase 1 and that doesn't help the valuation. The other forgotten fact is the phase 2 trials to expand the indication.
      Overall, as I wrote earlier, I see $7 by the end of July that is to get AU approval (Q2), Genentech presentation (May 30) and the results of Phase 2 (I have to look up for the date) can push it higher.

 
CRIS
1.38-0.01(-0.72%)Oct 20 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.